Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): CDC Grants for Public Health Research Dissertation (Panel G), Funding Opportunity Announcement (FOA) PAR07-231, Initial Review, 56857 [E9-26283]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 211 / Tuesday, November 3, 2009 / Notices
first-served basis. Opportunities to
address the panel during the meeting
will occur during discussion of each
topic, and speakers will be required to
register ahead of time. If you would like
to make a formal presentation during
the open public sessions, you must
register and provide an abstract of your
presentation by 5 p.m. e.s.t. on January
15, 2010. To speak, submit your name,
title, business affiliation (if applicable),
address, telephone and fax numbers,
and e-mail address to Adele Seifried
(see FOR FURTHER INFORMATION CONTACT).
FDA has included issues for comment
in section I of the SUPPLEMENTARY
INFORMATION section. You should also
identify by letter each issue you wish to
address in your presentation and the
approximate time requested for your
presentation.
FDA will do its best to accommodate
those who wish to speak. Individuals
and organizations with common
interests are urged to consolidate or
coordinate their comments and to
request time for a joint presentation.
FDA will determine the amount of time
allotted to each presenter. Persons
registered to make a formal presentation
should check in before the workshop. In
addition, we strongly encourage written
comments to the docket. Written or
electronic comments will be accepted
until February 24, 2010.
If you need special accommodations
because of disability, contact Adele
Seifried (see FOR FURTHER INFORMATION
CONTACT) at least 7 days before the
workshop.
mstockstill on DSKH9S0YB1PROD with NOTICES
III. Comments
Regardless of attendance at the public
workshop, interested persons may
submit written or electronic comments
to the Division of Dockets Management
(see ADDRESSES). Submit a single copy
of electronic comments or two paper
copies of any mailed comments, except
that individuals may submit one paper
copy. Comments should be identified
with the docket number found in
brackets in the heading of this
document. To ensure consideration,
submit comments by (see DATES).
Received comments may be seen in the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
IV. Transcripts
Please be advised that as soon as a
transcript is available, it will be
accessible at https://www.regulations
.gov. It may be viewed at the Division
of Dockets Management (see
ADDRESSES). A transcript will also be
available in either hardcopy or on CD–
ROM, after submission of a Freedom of
VerDate Nov<24>2008
18:15 Nov 02, 2009
Jkt 220001
Information request. Written requests
are to be sent to the Division of Freedom
of Information (HFI–35), Office of
Management Programs, Food and Drug
Administration, 5600 Fishers Lane, rm.
6–30, Rockville, MD 20857.
Dated: October 27, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–26397 Filed 11–2–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): CDC Grants for
Public Health Research Dissertation
(Panel G), Funding Opportunity
Announcement (FOA) PAR07–231,
Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned SEP:
Time and Date: 12:30 p.m.–4:30 p.m.,
December 2, 2009 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘CDC Grants for Public Health
Research Dissertation, FOA PAR07–231,
Panel G.’’
Contact Person for More Information:
Maurine Goodman, MA, MPH, Scientific
Review Administrator, CDC, 1600 Clifton
Road, NE., Mailstop D72, Atlanta, GA 30333,
Telephone (404) 639–4747.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: October 23, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–26283 Filed 11–2–09; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
56857
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development of a Companion
Diagnostic Kit To Detect Asparagine
Synthetase Expression Levels as a
Method To Screen for the Drug
Efficacy in Treatments for Pancreatic
Cancer, Ovarian Cancer, and Multiple
Myeloma
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. Patent Application
No. 12/281,589 and PCT Application
No. PCT/US07/05555 entitled
‘‘Materials and Methods Directed to
Asparagine Synthetase and
Asparaginase Therapies’’ (HHS Ref. No.
E–132–2006/2), to the French-based
ERYtech Pharma LLC which is located
in Lyon, France (with an additional
office in Philadelphia, Pennsylvania).
The patent rights in this invention have
been assigned to the United States of
America.
The prospective exclusive license
territory may be worldwide and the
field of use may be for to the use of the
Licensed Patent Rights limited to a
FDA-approved companion diagnostic
test predictive of L-asparaginase
therapeutic effect in the treatment of
pancreatic cancer, ovarian cancer, and
multiple myeloma as claimed in the
Licensed Patent Rights.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
January 4, 2010 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Samuel E. Bish, Ph.D.,
Licensing and Patenting Manager, Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
5282; Facsimile: (301) 402–0220; E-mail:
bishse@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
technology describes methods and
therapies involving asparagine
synthetase (ASNS) and L-asparaginase
E:\FR\FM\03NON1.SGM
03NON1
]]>Agencies
[Federal Register Volume 74, Number 211 (Tuesday, November 3, 2009)]
[Notices]
[Page 56857]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-26283]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): CDC Grants for Public Health Research
Dissertation (Panel G), Funding Opportunity Announcement (FOA) PAR07-
231, Initial Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned SEP:
Time and Date: 12:30 p.m.-4:30 p.m., December 2, 2009 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters To Be Discussed: The meeting will include the initial
review, discussion, and evaluation of applications received in
response to ``CDC Grants for Public Health Research Dissertation,
FOA PAR07-231, Panel G.''
Contact Person for More Information: Maurine Goodman, MA, MPH,
Scientific Review Administrator, CDC, 1600 Clifton Road, NE.,
Mailstop D72, Atlanta, GA 30333, Telephone (404) 639-4747.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: October 23, 2009.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E9-26283 Filed 11-2-09; 8:45 am]
BILLING CODE 4163-18-P
